The clinical trials listed on Celgene.com are Celgene-sponsored trials that are actively recruiting patients. After searching by disease, a list of available Celgene-sponsored trials will be displayed. Each listed trial contains a hyperlink to a website called ClinicalTrials.gov. On this website, you will find additional information about the study such as a study description, entry criteria, contact information and facility names where the study is being conducted.
| Study ID | Title |
| NCT03575351 | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas |
| NCT03554993 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects |
| NCT03539419 | Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain |
| NCT03521180 | A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma |
| NCT03484702 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma |
| NCT03467958 | An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease |
| NCT03464097 | A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease |
| NCT03440385 | Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease |
| NCT03440372 | Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease |
| NCT03435796 | Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells |
| NCT03435341 | Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
| NCT03363815 | A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) |
| NCT03342404 | A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia |
| NCT03337022 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis |
| NCT03324503 | A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis |
| NCT03310619 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) |
| NCT03290443 | A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. |
| NCT03288974 | Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea |
| NCT03284879 | Post-Marketing Surveillance Study of OTEZLA |
| NCT03283202 | Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors |
| NCT03257631 | A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors |
| NCT03220347 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas |
| NCT03194542 | A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence |
| NCT03161483 | A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus |
| NCT03142191 | A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis |
| NCT03106324 | A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant |
| NCT03098589 | Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) |
| NCT03097003 | A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium |
| NCT03096990 | A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium |
| NCT03001804 | Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients |
| NCT02954081 | APremilast After FumaRic Acid Ester Treatment |
| NCT02946333 | A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain |
| NCT02903069 | Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer |
| NCT02902900 | An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas |
| NCT02875184 | A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands |
| NCT02859324 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) |
| NCT02848001 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes |
| NCT02773030 | A Safety Study to Determine Dose and Tolerability of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
| NCT02740218 | A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice |
| NCT02692339 | Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma |
| NCT02677922 | A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) |
| NCT02658929 | Study of bb2121 in Multiple Myeloma |
| NCT02652494 | Observational Study of Apremilast in Patients With Psoriasis in The Netherlands |
| NCT02641002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) |
| NCT02635061 | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer |
| NCT02577406 | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation |
| NCT02555839 | Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice |
| NCT02555813 | Treatment of Pancreatic Cancer With Abraxane |
| NCT02551185 | ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors |
| NCT02531126 | Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis |
| NCT02494258 | A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders. |
| NCT02450877 | A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. |
| NCT02435992 | Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis |
| NCT02417285 | A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. |
| NCT02406742 | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| NCT02367196 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers |
| NCT02279654 | Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) |
| NCT02164955 | A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma. |
| NCT02031419 | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. |
| NCT01688011 | Connect® MDS/AML Disease Registry |
| No Results | |